Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

gain over time. To date, the only highly effective treatment option is surgical and limited to the minority of patients who have advanced to the most severe forms of obesity," said Steven R. Smith, M.D., professor and assistant director of clinical research at the Pennington Biomedical Research Center. "Providing the over 80 million overweight and obese Americans who have a BMI less than 35 kg/m2 with safe treatment options that offer compelling weight loss would be a significant advancement in obesity drug development."

The combination therapy was well tolerated, and no cardiovascular or neuropsychiatric (such as anxiety or depression) safety signals were observed. Consistent with previous clinical experience, the most common side effects seen with pramlintide/metreleptin combination treatment were injection site adverse events and nausea, which were mostly mild or moderate and transient in nature.

"These findings provide us with valuable data that will inform our clinical and product development strategy moving forward," said Christian Weyer, M.D., vice president, corporate development, diabetes and obesity at Amylin Pharmaceuticals. "Our integrated neurohormonal approach to obesity provides a broad research and development platform that has the potential to yield transformational therapies that address a range of unmet patient needs across the various classes of obesity."

Study Details

This Phase 2, 28-week, double-blind, placebo-controlled multi-center study randomized 608 obese or overweight patients with a BMI ranging from 27-45 kg/m2. Patients were well-distributed across this BMI range, with approximately 40% of patients at a starting BMI less than 35 kg/m2. Following a one-week placebo lead-in period, study subjects were randomized in a balanced fashion to receive twice-daily therapy with one of the following eight treatment regimens: 1) placebo/placebo; 2) pramlintide 360 mcg/placebo; 3)
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Gallus BioPharmaceuticals , ... and manufacturing organization (CMO) announced today that it ... oncology company focused on the development of innovative ... the anti-prostate specific membrane antigen (PSMA) monoclonal antibody ... Under the agreement the antibody will be produced ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... California (PRWEB) August 20, 2014 ... develop and apply the most complete climate and ... and demanding climate change issues. , Eight national ... forces with the National Center for Atmospheric Research, ... the new effort. Other participating national laboratories include ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... and beyond have been given a new Web-based tool ... interns among the graduates and students of Wisconsins universities ... brings together the career services offices at the University ... resources of the other four-year campuses of the UW ...
... , a health care software and services company, announced ... version 2.5. The updated product includes integration with FUSION ... billing workflow to run from a single, unified end-user ... create productivity improvements for the radiologist and technologist by ...
... days, Al Jacobs taught students about the power of doubling by talking ... and the pads doubled in area every day: How long would it ... cover a pond of 250,000 square feet? , ,Only 17 days, thanks ... 32 and so on, until on the 17th day, 131,072 square feet ...
Cached Biology Technology:New Web site makes recruiting from Wisconsin universities easier 2Merge eFilm announces release of FUSION RIS version 2.5 2Doubling the lily pads: Controlling the explosion in health care costs 2Doubling the lily pads: Controlling the explosion in health care costs 3
(Date:8/21/2014)... growing in near darkness use a previously unknown process ... research team led by a Penn State University scientist ... research aimed at improving plant growth, harvesting energy from ... occurring on Lake Erie and other lakes worldwide. A ... Science Express edition of the journal ...
(Date:8/21/2014)... eczema and other itchy, flaky maladies in humans has ... coral reefs and the extreme environments of arctic soils ... scientific journal PLOS Pathogens considers the diversity, ... Malassezia in light of new insights gained ... , University of Hawai,i at Mānoa scientist Anthony Amend ...
(Date:8/21/2014)... landmark study aimed at improving the food intake, health ... care homes is among three projects at the University ... from the Canadian Institutes of Health Research (CIHR). ... Health Sciences at Waterloo, and a Schlegel research chair ... years to investigate why many Canadians living in long-term ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2
... Using a carbon nanotube instead of traditional silicon, Cornell ... that hopefully will lead to much more efficient ways of ... on rooftops. The researchers fabricated, tested and measured a ... carbon nanotube. Reported online Sept. 11 in the journal ...
... of Texas at San Antonio (UTSA) has received a ... (NSF) to study nanomaterials and their biomedical applications. ... Education in Materials grant, is the second major NSF ... announced the receipt of $5 million to establish a ...
... diabetes, not only do waistlines matter to women, but so does ... a team of Swedish researchers was just published online in the ... of normal weight develop type 2 diabetes, despite not having any ... fat cells and the development of type 2 diabetes may give ...
Cached Biology News:Carbon nanotubes could make efficient solar cells 2UTSA Physics Department receives $2.7 million to study nanomaterials 2Size of fat cells and waist size predict type 2 diabetes in women 2
... Life Sciences provides cost effective cell culture ... or monoclonal antibodies. Quality at a reasonable ... you require research or commercial product, we ... methods such as roller bottles, hollow fiber, ...
... for hunting and analyzing the rare ... EST sequencing projects, microarrays, functional screenings ... well suited for the normalization of ... though, is specially developed for normalization ...
... Application: The Panorama Mouse/Rat Tissue Extract Protein ... expression in various tissue extracts. The expression ... detected using a protein specific antibody. When ... is visualized by a sensitive chemiluminescent or ...
... StabilGuard Choice Microsphere/Microarray Stabilizer is a ... Plus Stabilizer. This product is an ... a PBS buffer (phosphate buffered saline), pH ... a combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: